Using Champions' PDX Models for Preclinical Validation of ERK Pathway Inhibitors

Cellular responses to external stimuli from molecules such as growth factors, mitogens, cytokines, and the extracellular matrix are governed in part by signal transduction networks.

One such network, the ERK pathway, is a central and important signaling pathway that translates extracellular cues from mitogens and growth factors into regulated outputs affecting diverse cellular functions such as proliferation, inflammation, metabolism, differentiation, and apoptosis.

This case study highlights the potential of targeting the ERK pathway as a therapeutic strategy for a variety of tumor types while leveraging Champions' TumorGraft^® models